Robert E. Kalb

2.6k total citations
40 papers, 1.3k citations indexed

About

Robert E. Kalb is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Robert E. Kalb has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 12 papers in Dermatology and 7 papers in Rheumatology. Recurrent topics in Robert E. Kalb's work include Psoriasis: Treatment and Pathogenesis (16 papers), Dermatology and Skin Diseases (9 papers) and Autoimmune Bullous Skin Diseases (3 papers). Robert E. Kalb is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (16 papers), Dermatology and Skin Diseases (9 papers) and Autoimmune Bullous Skin Diseases (3 papers). Robert E. Kalb collaborates with scholars based in United States, Canada and Netherlands. Robert E. Kalb's co-authors include Mark Lebwohl, Marc E. Grossman, Bruce Strober, Gerald D. Weinstein, Abby S. Van Voorhees, Bruce F. Bebo, Neil J. Korman, Sylvia Hsu, Mark H. Kaplan and Amanda Robinson and has published in prestigious journals such as JAMA, The American Journal of Medicine and Journal of the American Geriatrics Society.

In The Last Decade

Robert E. Kalb

39 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert E. Kalb United States 18 757 476 237 220 214 40 1.3k
Vito Di Lernia Italy 24 572 0.8× 915 1.9× 363 1.5× 295 1.3× 269 1.3× 113 1.7k
Sylvia Hsu United States 18 228 0.3× 474 1.0× 350 1.5× 223 1.0× 207 1.0× 78 1.2k
Camille Hua France 18 745 1.0× 462 1.0× 114 0.5× 179 0.8× 172 0.8× 43 1.7k
Ricardo Romiti Brazil 26 1.0k 1.4× 896 1.9× 307 1.3× 383 1.7× 460 2.1× 138 2.1k
Enrique Rivas Mexico 9 1.4k 1.8× 763 1.6× 178 0.8× 337 1.5× 250 1.2× 13 1.7k
Silvia Helou Argentina 10 1.3k 1.7× 727 1.5× 326 1.4× 332 1.5× 245 1.1× 16 1.7k
Ricardo Niklas Werner Germany 19 364 0.5× 794 1.7× 585 2.5× 126 0.6× 97 0.5× 68 1.5k
Shinichi Imafuku Japan 25 1.2k 1.6× 1.2k 2.6× 394 1.7× 464 2.1× 314 1.5× 182 2.3k
Derek Blankenship United States 21 1.1k 1.5× 172 0.4× 645 2.7× 187 0.8× 100 0.5× 35 2.0k
Natalie J. Prescott United Kingdom 22 722 1.0× 153 0.3× 329 1.4× 126 0.6× 125 0.6× 45 1.9k

Countries citing papers authored by Robert E. Kalb

Since Specialization
Citations

This map shows the geographic impact of Robert E. Kalb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Kalb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Kalb more than expected).

Fields of papers citing papers by Robert E. Kalb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Kalb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Kalb. The network helps show where Robert E. Kalb may publish in the future.

Co-authorship network of co-authors of Robert E. Kalb

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Kalb. A scholar is included among the top collaborators of Robert E. Kalb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Kalb. Robert E. Kalb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wan, Marilyn T., Megan H. Noe, Daniel B. Shin, et al.. (2019). 538 The vascular inflammation in psoriasis (VIP) trial: A secondary analysis of patient reported outcomes for patients treated with adalimumab, phototherapy, or placebo. Journal of Investigative Dermatology. 139(5). S93–S93. 1 indexed citations
2.
Noe, Megan H., Marilyn T. Wan, Daniel B. Shin, et al.. (2019). Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. Journal of the American Academy of Dermatology. 81(4). 923–930. 12 indexed citations
3.
Takeshita, Junko, Shuwei Wang, Daniel B. Shin, et al.. (2014). Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. Journal of the American Academy of Dermatology. 71(6). 1167–1175. 17 indexed citations
4.
Yeung, Howa, Joy Wan, Abby S. Van Voorhees, et al.. (2012). Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 68(1). 64–72. 94 indexed citations
5.
Robinson, Amanda, Abby S. Van Voorhees, Sylvia Hsu, et al.. (2012). Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 67(2). 279–288. 170 indexed citations
6.
Kalb, Robert E., Bruce Strober, Gerald D. Weinstein, & Mark Lebwohl. (2012). Methotrexate and psoriasis: Consensus conference. Journal of the American Academy of Dermatology. 66(4). 689–690. 1 indexed citations
7.
Kalb, Robert E., Bruce Strober, Gerald D. Weinstein, & Mark Lebwohl. (2011). Methotrexate and psoriasis: Consensus conference. Journal of the American Academy of Dermatology. 64(6). 1179–1179. 4 indexed citations
8.
Voorhees, Abby S. Van, Mark Lebwohl, Neil J. Korman, et al.. (2009). Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 60(6). 962–971. 79 indexed citations
9.
Kalb, Robert E., Bruce Strober, Gerald D. Weinstein, & Mark Lebwohl. (2009). Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. Journal of the American Academy of Dermatology. 60(5). 824–837. 246 indexed citations
10.
Lebwohl, Mark, Jerry Bagel, Joel M. Gelfand, et al.. (2007). From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology. 58(1). 94–105. 84 indexed citations
11.
Kalb, Robert E., et al.. (2007). Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. British Journal of Dermatology. 158(3). 607–610. 30 indexed citations
12.
Kalb, Robert E., et al.. (2007). Infliximab in the treatment of psoriasis in patients previously treated with etanercept. Journal of the American Academy of Dermatology. 57(1). 120–125. 18 indexed citations
13.
Kalb, Robert E.. (1991). Persistent light reaction to hexachlorophene. Journal of the American Academy of Dermatology. 24(2). 333–334. 6 indexed citations
14.
Kalb, Robert E., et al.. (1989). Penile Encrustation Due to a Condom Catheter. Journal of the American Geriatrics Society. 37(2). 160–162. 5 indexed citations
15.
Kalb, Robert E., et al.. (1988). Sarcoidosis with subcutaneous nodules. The American Journal of Medicine. 85(5). 731–736. 25 indexed citations
16.
Kalb, Robert E., et al.. (1987). Allergic contact dermatitis from bacitracin. Journal of the American Academy of Dermatology. 17(4). 592–594. 11 indexed citations
17.
Fradin, Mark S., Robert E. Kalb, & Marc E. Grossman. (1987). Recurrent Cutaneous Vascuiitis in Cystic Fibrosis. Pediatric Dermatology. 4(2). 108–111. 11 indexed citations
18.
Sherr, David L., Karen S. Fountain, & Robert E. Kalb. (1986). Cutaneous Metastases from Chondrosarcoma. The Journal of Dermatologic Surgery and Oncology. 12(2). 146–149. 9 indexed citations
19.
Kalb, Robert E.. (1985). Pterygium Formation due to Sarcoidosis. Archives of Dermatology. 121(2). 276–276. 15 indexed citations
20.
Klein, Gunnar, et al.. (1968). [Allopurinol in the treatment of gout].. PubMed. 27(11). 455–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vito Di Lernia Breakdown of academic impact, for papers by Sylvia Hsu Breakdown of academic impact, for papers by Camille Hua Breakdown of academic impact, for papers by Ricardo Romiti Breakdown of academic impact, for papers by Enrique Rivas Breakdown of academic impact, for papers by Silvia Helou Breakdown of academic impact, for papers by Ricardo Niklas Werner Breakdown of academic impact, for papers by Shinichi Imafuku Breakdown of academic impact, for papers by Derek Blankenship Breakdown of academic impact, for papers by Natalie J. Prescott
Rankless by CCL
2026